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1. Introduction 
Antibody phage display is an in vitro technology to generate recombinant antibodies. In 
particular for pathogens or toxins, antibody phage display is an alternative to hybridoma 
technology, since it circumvents the limitations of the immune system. Furthermore, phage 
display allows generation of human antibodies when either immunised patients are not 
available or immunisation is not ethically feasible. 
Equine encephalitis viruses, like VEEV, WEEV and EEEV, belong to the Alphavirus group. 
Several species and subspecies of this family are pathogenic for man and are recognized as 
potential agents of biological warfare and terrorism. In this review, we describe the 
generation of human antibodies from naive antibody gene libraries and macaque antibodies 
from immune antibody gene libraries. Furthermore, we give an overview about phage 
display derived recombinant antibodies against equine encephalitis viruses for diagnostics 
and therapy. 
2. Short introduction to encephalitis viruses 
Venezuelan equine encephalitis virus (VEEV), Western equine encephalitis virus (WEEV) and 
Eastern equine encephalitis virus (EEEV) were first isolated in the 1930s and belong to the 
Alphavirus genus within the Togaviridae family (Giltner and Shahan, 1933; King, 1939; Kubes 
and Ríos, 1939; Meyer et al., 1931; Powers et al., 2001; Weaver et al., 2004). Mosquitoes are the 
biological vectors of theses viruses and equine species and man are periodically infected 
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(Strauss and Strauss, 1994). In the past epidemics caused by these viruses occured in North, 
Central and South America. These viruses can spread to the human central nervous system 
(CNS) causing symptoms ranging from mild febrile reactions to encephalitis, often resulting in 
fatal and permanent neurologic damages. The severity of the illness depends on virus strain, 
age of patients as well as dose and route of infection (Calisher, 1994; Deresiewicz et al., 1997; 
Feemster, 1938; Hoke, 2005; Leitenberg, 2001; Letson et al., 1993; Rivas et al., 1997; Rozdilsky et 
al., 1968; Sanchez et al., 1984; Sellers and Maarouf, 1993; Sudia et al., 1975; Weaver et al., 1996). 
Moreover, alphaviruses can be produced in large quantities, are moderately easy to 
disseminate and are highly infectious as aerosols (Phillpotts, 2006; Reed et al., 2005). Therefore, 
VEEV, WEEV and EEEV are potential biological weapons (Hawley and Eitzen, 2001). All three 
encephalitis virus species are classified as Bioterrorism Agent Category B by the Center of 
Disease Control (CDC) (http://www.bt.cdc.gov/agent/agentlist-category.asp). 
For rapid detection, diagnosis and treatment of VEEV, WEEV and EEEV antibodies are 
indispensable tools and potential therapeutics. 
3. Antibody phage display 
Production of polyclonal antibodies by immunisation of animals is a method established for 
more than a century. The first antibody serum was produced in horses and directed against 
diphtheria (von Behring and Kitasato, 1890). Hybridoma technology was the next milestone, 
allowing the production of monoclonal antibodies (Köhler and Milstein, 1975). Hybridoma 
technology has drawbacks like limited number of candidates, possible instability of aneuploid 
cell lines (Pauza et al., 1993), inability to provide antibodies against highly conserved antigens 
and most of all its limited application to generate human antibodies (Winter and Milstein, 
1991). Hybridoma technology thus essentially allows isolation of murine antibodies which 
have a broad detection range and can be applied for diagnostic or research uses. However, 
their therapeutic applications are limited because repeated administration of murine 
antibodies can cause human anti-mouse antibody reaction (HAMA), in turn leading to a 
diminution of the antibody half-life and to severe side effects including anaphylactic side 
effects (Courtenay-Luck et al., 1986; Tjandra et al., 1990). These difficulties might be alleviated 
by engineering these antibodies to reduce their fraction of murine origin. Chimerised 
antibodies have murine variable regions, retaining binding capacity of the original murine 
antibody, expressed in fusion with human constant regions. But, these variable murine regions 
are still large enough to be a cause for adverse reactions so that the smaller hypervariable 
regions, in direct contact with the antigen, might be preferred as the only murine part retained 
in the therapeutic molecule. The corresponding engineering process is known as 
humanisation, which is however more difficult to implement than chimerisation. Another 
possibility is to utilise transgenic mice whose loci coding antibodies have been replaced by 
their human counterparts. With these mice, human antibodies can be generated by hybridoma 
technology but these transgenic animals are available in a very limited number of laboratories 
only (Fishwild et al., 1996; Jakobovits, 1995; Lonberg and Huszar, 1995; Nelson et al., 2010). For 
the isolation of antibodies directed against toxins, animals are immunised by non-toxic 
subunits or even selected domains from these subunits (Pelat et al., 2009a; Pelat et al., 2007; 
Scotcher et al., 2010; Winterroth et al., 2010). 
A technology which circumvents the limitations of the immune system is antibody phage 
display. This technology is completely independent from any immune system by an in vitro 
selection process. The display method most commonly used today is based on the work of 
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George P. Smith (Smith, 1985) on filamentous phage, which infect E. coli. By this technology, 
genotype and phenotype of a polypeptide e.g. an antibody are linked by fusing the antibody-
encoding DNA to the coat protein III gene (gIII) of the filamentous bacteriophage M13. The 
resulting antibody::pIII fusion protein is displayed on the surface of phage particles, thus 
allowing affinity isolation of the antibody and consequently the purification of its coding DNA 
present within the phage (Breitling et al., 1991; Clackson et al., 1991; McCafferty et al., 1990). 
In fact only antibody fragments like single chain fragment variable (scFv) or fragment 
antigen binding (Fab) are used routinely for phage display (Hoet et al., 2005; Hust et al., 
2010), due to limitations of the E. coli protein folding machinery which can express full-sized 
IgGs only in rare cases (Mazor et al., 2007; Simmons et al., 2002). ScFv fragments consist of 
the variable domains of the heavy and light chain (Fv fragment) connected by a peptide 
linker (Bird et al., 1988; Huston et al., 1988). Other used formats for phage display are single 
chain Fabs (scFab), human VH domains (dAbs) and the variable domains of camel heavy 
chains (VHHs) (Holt et al., 2003; Hust et al., 2007b; Muyldermans, 2001; Muyldermans et al., 
2009). Another interesting „antibody“ format for phage display are immunoglobulins of 
sharks (IgNARs), which are very resistant to denaturation and well suitable for diagnostics. 
(Flajnik and Dooley, 2009; Nuttall et al., 2001; Nuttall et al., 2004). 
The phage-displayed libraries are built from immunised or non-immunised lymphocyte 
donors or from synthetic repertoires. Libraries using the naïve IgM repertoire - the primary 
immune response - of a donor or synthetic antibody sequences are summarised as „single-
pot“ or universal libraries. These libraries are designed to isolate antibody fragments 
binding to every possible antigen, at least in theory (Dübel et al., 2010; Winter et al., 1994). 
Different types of universal libraries are available. Naïve libraries are constructed from 
rearranged V genes from B cells (IgM) of non-immunised donors. Examples for this library 
type are the naive human Fab library constructed by de Haard et al. (de Haard et al., 1999) 
and the HAL scFv libraries (Hust et al., 2011). Semi-synthetic libraries are constructed from 
unrearranged V genes from pre B germline cells  (Griffiths et al., 1994) or from an antibody 
framework (Pini et al., 1998) in which one or several complementarity determining regions 
(CDR), including always the CDR H3, are randomised. For the FAB310 antibody gene 
library, a combination of naive and synthetic repertoire was used. Here, light chains from 
autoimmune patients were combined with a Fd fragment containing synthetic CDR1 and 
CDR2 in the human VH3-23 framework and naive CDR3 regions, derived from autoimmune 
patients (Hoet et al., 2005). Fully synthetic libraries are made of human frameworks with 
randomised CDR cassettes (Knappik et al., 2000; Rothe et al., 2008). Universal libraries have 
a repertoire of 108 - 1011 independent clones as molecular repertoire for phage display 
selection procedures. The difficulty of naïve libraries is that antibodies isolated thereof have 
lower affinities as hybridoma derived antibodies. Affinity and stability of the antibodies 
selected by phage display can be increased by additional in vitro affinity maturation steps 
(Finlay et al., 2009; Kobayashi et al., 2010; Thie et al., 2011; Thie et al., 2009). 
To date, antibody phage display was used for the generation of antibodies against a large 
panel of human pathogenic viruses by using either recombinant viral proteins or complete 
virus particles for panning. Naïve antibody gene libraries were used to generate antibodies 
against Sin nombre virus (Velappan et al., 2007), Dengue virus (Cabezas et al., 2008; 
Moreland et al., 2010), Hepatitis C virus (Songsivilai and Dharakul, 1998), Influenza virus 
(Lim et al., 2008) or VEEV (Kirsch et al., 2008). 
Opposite to these naive libraries are “immune libraries” which are constructed from 
antibody V-genes isolated from IgG secreting plasma cells from blood or bone marrow of 
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immunised donors. V genes of these libraries contain hypermutations and are affinity 
matured.  From these immune libraries, human antibodies usable for therapeutic purposes 
against infectious pathogens (Clackson et al., 1991; Pelat et al., 2007; Schütte et al., 2009), 
including viruses (Duggan et al., 2001; Hunt et al., 2010; Kang et al., 2006; Sun et al., 2009; 
Throsby et al., 2008) have been isolated. Generally, immune libraries have a size of 106-108 
independent clones, but can not be built for each antigen of interest, because man cannot be 
immunized with all antigens for ethical and practical reasons. An alternative are macaque 
immune libraries. The antibody genes of non-human primates (NHP) are closely related to 
human antibody genes (Pelat et al., 2009b) and might easily be humanised or germline 
humanised. In this latter case, the macaque amino acid sequence of the antibody is first 
compared with the corresponding human germline sequence. Differing macaque amino acid 
sequences are localised and are replaced by their human germline counterparts (Pelat et al., 
2008; Pelat and Thullier, 2009) with respect to their affinity. Human germline sequences 
belong to the immunological self and are generally perfectly tolerated. However, this 
approach can even be used to reduce the potential immunogenicity of human antibodies. 
The in vitro isolation of antibody fragments from libraries is performed independently from 
their immune or naïve origin. It relies on the binding activity of these antibody fragments 
and is called „panning“ (Fig. 1), referring to the gold digger's tool (Parmley and Smith, 
1988). For this panning, the antigen (a protein or a complete organism like a virus) is 
immobilised to a solid surface, mainly plastic surfaces like polystyrene tubes (Hust et al., 
2002) or 96 well microtitre plates (Hust et al., 2011) and incubated with antibody phage of 
the antibody gene library. During this incubation step, chemical (e.g. pH), physical (e.g. 
temperature) or biological (e.g. competitor) parameters can be controlled to select antibodies 
which are able to bind the antigen. Antibody phage particles which bind weakly to the 
antigen and the vast excess of non-binding antibody phage are removed by strigent 
washing. Specifically binding antibody phage are eluted (e.g. by trypsin or pH shift) and 
reamplified by infection of E. coli. Subsequently, the phagemid bearing E. coli are infected 
with a helperphage, mainly M13K07, to produce new antibody phage which can be used for 
further panning rounds until a significant enrichment of antigen specific phage is achieved. 
Usually two or three panning rounds are necessary to select specifically binding antibody 
fragments. After panning, soluble individual monoclonal antibody fragments or antibody 
phage are produced and specific antigen binding is analysed by ELISA to identify 
individual binders. Afterwards, these individual binders can be sequenced and further 
biochemically characterised (Hust et al., 2007a; Winter et al., 1994). This panning process can 
also be performed in a high-throughput manner (Buckler et al., 2008; Hallborn and Carlsson, 
2002; Hust et al., 2011; Konthur et al., 2005). Because the gene sequence of the binder is 
available, the antibody – depending on the desired application – can be converted into 
different antibody formats (e.g. scFv-Fc fusion or IgG) and produced in different production 
hosts (Hust et al., 2011; Schirrmann et al., 2008). In summary, recombinant antibody 
fragments derived from phage display can be adapted to the final assay requirements. 
4. Antibodies for diagnostics and therapy of encephalitis viruses generated 
by phage display 
In the beginning of 2011, 29 therapeutic monoclonal antibodies were approved in the USA 
or EU. For further antibodies approval is pending (http://www.landesbioscience.com 
/journals/mabs/about). The most admitted therapeutic antibodies are for cancer and   
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Fig. 1. Schematic overview about antibody gene library construction and the selection of 
binders (panning). This figure is a modified version of a former figure (Schirrmann and 
Hust, 2010). 
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autoimmune diseases (Dübel, 2007). Mechanisms of therapeutic antibodies are manifold and 
include neutralisation of substances e.g. toxins (Pelat et al., 2007) or cytokines like tumor 
necrosis factor (TNF) alpha (Alonso-Ruiz et al., 2008), blocking of receptors like epidermal 
growth factor receptor (EGFR) (Peeters et al., 2009), binding to cells and modulating the host 
immune system (Chatenoud and Bluestone, 2007), or combinations of these effects (Adams 
and Weiner, 2005). Interestingly, todate no recombinant antibodies are approved for the 
treatment of viral infections. 
Rapid diagnosis of equine encephalitis is essential to allow an appropriate medical 
treatment, preventing viral replication. This may be allowed by point-of-care diagnosis tests 
based on antibodies or antibody fragments. After successful diagnosis, specific treatment 
might be considered and the use of recombinant (chimerized, humanized or human) 
neutralising antibodies is one choice. Also a prophylactic use of these recombinant 
antibodies might be considered for a time-limited protection, as human antibodies have a 
half-life of around 3 weeks in man (Eklund et al., 1982). 
Since the administration of the original vaccine VEEV strain, TC83, developed in the sixties, 
had serious side effects to man (MCKINNEY et al., 1963), murine, macaque, humanised and 
human antibodies have been generated against VEEV by antibody phage display as an 
alternative in recent years. VEEV TC83 was used for example for the immunisation of mice 
from which the protective monoclonal antibody mAb 3B4C-4 was generated and later  
humanised (Hunt et al., 2006; Roehrig et al., 1982). The resulting antibody, mAb Hy4, turned 
out to be as protective as the original mouse antibody as demonstrated by virus challenge in 
Swiss Webster mice (Hunt et al., 2006). A further neutralising humanised antibody was 
developed by Hu et al (Hu et al., 2010). 
The first anti-VEEV recombinant antibody fragments were derived from the murine IgG 
mAb 5B4D-6 by molecular cloning (Alvi et al., 1999). Murine scFvs aimed for diagnostic use 
were also isolated by phage display using immune libraries (Duggan et al., 2001), as phage 
display allows testing more candidates than hybridoma technology thus improving the 
search for selected specificities. Later, protective murine antibody fragments were generated 
using phage display. The broadly reacting scFv CUF37 was converted into the murine IgG2a 
format; this antibody was not neutralising in vitro but protective in vivo (O’Brien et al., 2009). 
The humanised version of this antibody (hu1A3B-7) protected mice in challenge 
experiments using the VEEV strain Trinidad Donkey (TrD) (Goodchild et al., 2011). 
Regarding human antibody fragments, a panel of scFvs was selected for diagnostic assays 
from the naïve human libraries HAL4/7 using the antibody-displaying phage particles 
directly (Kirsch et al., 2008). Further human antibodies for therapeutic purposes were 
isolated using Fab (Fragment antigen binding) antibody phage display. The human immune 
library was constructed from sera of two VEEV strain TC-83 immunised US soldiers and 
two neutralising antibody fragments were identified. Hunt and coauthors suggested to use 
mAb F5 in combination with the earlier isolated humanised antibody mAb Hy4 for 
therapeutic purposes because they bind to different epitopes of the VEEV E2 glycoprotein 
(Hunt et al., 2010).  The authors of the present review isolated a macaque scFv from an 
immune phage-displayed library directed against VEEV. Expressed as fusion with human 
constant regions, the resulting scFv-Fc protected mice against lethal challenge with 
Venezuelan equine encephalitis viruses (Rülker et al., in preparation). 
To our knowledge no anti-WEEV antibody fragments derived from any kind of library is 
published. However, scFvs were generated from the murine IgGs 11D2 (Das et al., 2004; Xu 
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et al., 1999) and 10B5 E7E2 (Long et al., 2000) for diagnostic purposes. The authors of this 
review generated scFvs against WEEV by phage display using a macaque immune antibody 
gene library (Rülker et al. in preparation), both for diagnosis and therapeutic purposes. 
Regarding EEEV, to our knowledge no recombinant human or murine antibodies have been 
published. 
“At present there is no FDA-approved medical treatment for infection with these viruses.” 
(Reichert et al., 2009). However, antibody phage display and other techniques have already 
delivered human or human-like antibodies as leads for the treatment or prophylaxis of 
equine encephalitis. Alternatively, the epitopes of these antibodies might also be candidate-
vaccine. 
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